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Articles

Causes and incidence of community-acquired serious
infections among young children in south Asia (ANISA):
an observational cohort study
Samir K Saha*, Stephanie J Schrag*, Shams El Arifeen, Luke C Mullany, Mohammad Shahidul Islam, Nong Shang, Shamim A Qazi, Anita K M Zaidi,
Zulfiqar A Bhutta, Anuradha Bose, Pinaki Panigrahi, Sajid B Soofi, Nicholas E Connor, Dipak K Mitra, Rita Isaac, Jonas M Winchell, Melissa L Arvay,
Maksuda Islam, Yasir Shafiq, Imran Nisar, Benazir Baloch, Furqan Kabir, Murtaza Ali, Maureen H Diaz, Radhanath Satpathy, Pritish Nanda,
Bijaya K Padhi, Sailajanandan Parida, Aneeta Hotwani, M Hasanuzzaman, Sheraz Ahmed, Mohammad Belal Hossain, Shabina Ariff, Imran Ahmed,
Syed Mamun Ibne Moin, Arif Mahmud, Jessica L Waller, Iftekhar Rafiqullah, Mohammad A Quaiyum, Nazma Begum, Veeraraghavan Balaji,
Jasmin Halen, A S M Nawshad Uddin Ahmed, Martin W Weber Davidson, H Hamer, Patricia L Hibberd, Qazi Sadeq-ur Rahman,
Venkat Raghava Mogan, Tanvir Hossain, Lesley McGee, Shalini Anandan, Anran Liu, Kalpana Panigrahi, Asha Mary Abraham, Abdullah H Baqui

Summary

Background More than 500 000 neonatal deaths per year result from possible serious bacterial infections (pSBIs), but
the causes are largely unknown. We investigated the incidence of community-acquired infections caused by specific
organisms among neonates in south Asia.
Methods From 2011 to 2014, we identified babies through population-based pregnancy surveillance at five sites in
Bangladesh, India, and Pakistan. Babies were visited at home by community health workers up to ten times from age
0 to 59 days. Illness meeting the WHO definition of pSBI and randomly selected healthy babies were referred to study
physicians. The primary objective was to estimate proportions of specific infectious causes by blood culture and
Custom TaqMan Array Cards molecular assay (Thermo Fisher, Bartlesville, OK, USA) of blood and respiratory
samples.
Findings 6022 pSBI episodes were identified among 63 114 babies (95·4 per 1000 livebirths). Causes were attributed in
28% of episodes (16% bacterial and 12% viral). Mean incidence of bacterial infections was 13·2 (95% credible interval [CrI]
11·2–15·6) per 1000 livebirths and of viral infections was 10·1 (9·4–11·6) per 1000 livebirths. The leading pathogen
was respiratory syncytial virus (5·4, 95% CrI 4·8–6·3 episodes per 1000 livebirths), followed by Ureaplasma spp
(2·4, 1·6–3·2 episodes per 1000 livebirths). Among babies who died, causes were attributed to 46% of pSBI episodes,
among which 92% were bacterial. 85 (83%) of 102 blood culture isolates were susceptible to penicillin, ampicillin,
gentamicin, or a combination of these drugs.
Interpretation Non-attribution of a cause in a high proportion of patients suggests that a substantial proportion of
pSBI episodes might not have been due to infection. The predominance of bacterial causes among babies who died,
however, indicates that appropriate prevention measures and management could substantially affect neonatal
mortality. Susceptibility of bacterial isolates to first-line antibiotics emphasises the need for prudent and limited use
of newer-generation antibiotics. Furthermore, the predominance of atypical bacteria we found and high incidence of
respiratory syncytial virus indicated that changes in management strategies for treatment and prevention are needed.
Given the burden of disease, prevention of respiratory syncytial virus would have a notable effect on the overall health
system and achievement of Sustainable Development Goal.
Funding Bill & Melinda Gates Foundation
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
The Millennium Development Goals led to reductions in
deaths among children younger than 5 years by 56%, from
12·7 million in 1990 to 5·6 million, in 2016 worldwide.1 In
south Asia the reduction was 64%, from 4·8 million
to 1·7 million, but the percentage of neonatal deaths
increased from 45% in 1990 to 59% in 2016.
The main causes of neonatal deaths in low-income
and middle-income countries are prematurity, intra
partum-related events, severe infections, and congenital

anomalies.1–3 Severe infections, including sepsis,
meningitis, and pneumonia, are estimated to cause
about a third of the 2·6 million neonatal deaths globally
or often lead to long-term disabilities.4 Pre
vention of
neonatal infections will be necessary to achieve
Sustainable Development Goal 3 (ensure healthy lives
and promote wellbeing for all at all ages) and the
objectives of the Every Woman Every Child initiative.5,6
Although neonatal illness is commonly referred to as
possible serious bacterial infection (pSBI), the causes
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Research in context
Evidence before this study
The Millennium Development Goals reinforced the global
commitment to improve child survival and have led to
mortality in children younger than 5 years being lowered by
56% from 12·7 million in 1990 to 5·6 million in 2016. In
south Asian countries, mortality in this age group has been
reduced by 64%, from 4·8 million to 1·7 million. Neonatal
mortality, however, increased from 45% to 59% between
1990 and 2017. We searched PubMed and Ovid, without date
restrictions, with 51 combinations of the keywords “neonatal
infections”, “South Asia”, “sepsis”, “young infant”, “etiology”,
“low income countries”, “clinical algorithm”, and “surveillance”.
This search yielded 317 references that were relevant to our
research questions. The main causes of neonatal deaths seem
to be prematurity, intrapartum complications, severe
infection, and congenital anomalies. Severe infection is
addressed by treatment and prevention policies focused on
clean delivery at birth, breastfeeding, appropriate antibiotic
therapy for ill babies, and vaccination. Nevertheless, the causes
of most possible serious bacterial infections (pSBIs) remain
elusive. In 2012, an estimated 6·9 million neonates worldwide
met the WHO definition for pSBI—ie, referral to hospital and
antibiotic treatment—although in studies bacteria have been
detected by culture in only 5–10% of samples. Information
about viral causes of illness is even scarcer. Treatment remains
mostly empirical, particularly in developing countries, where
most data on antimicrobial resistance derive from hospitalacquired infections. Given the gap in knowledge about causes
of pSBI in neonates and the widespread use of treatment with
antibiotics, multidrug resistance is a concern. Few studies have
included neonates, and even fewer babies on the day of birth,
when most neonatal deaths occur. Moreover, studies in
low-income and middle-income countries have mostly been
hospital based and enrolled babies with pSBI who were seeking
health care. In many parts of south Asia, home births are still
common and seeking care in the days after birth is rare, even
when referred by a community health worker.

remain largely unknown,7,8 which is an important
impediment to the design of effective prevention and
management programmes.
Few data are available on the annual number of pSBI
episodes in south Asia, despite this region having
the highest number worldwide (3·5 million).2,9 Deter
mination of the causes of pSBI in neonates has
depended on isolation of bacteria by blood culture,
which is deemed to be the gold standard test despite
poor sensitivity. Two outpatient-based WHO studies
done in multiple countries and a population-based
study done in low-income and middle-income countries
yielded bacterial isolates from less than 10% of babies
with pSBI.10–12 A study in India showed 10% positivity by
blood culture, with organisms being predominantly
Gram-negative (69%).13 A study in Bangladesh examined
146

Added value of this study
We designed the ANISA study to assess unanswered questions
specifically in developing countries, in a large sample of
pregnant women and babies, by testing blood and respiratory
samples from those with symptoms and from healthy
controls. We generated population-based evidence on the
causes of pSBI through community-wide pregnancy
surveillance and enrolment of babies born at home and in
health facilities. We included areas with high child mortality
and those with state-of-the-art diagnostic services. Stringent
protocols were put in place to minimise blood-culture
contamination and an external expert panel confirmed
classifications of blood culture isolates. As well as blood
culture, we incorporated molecular testing in almost
2000 healthy babies and used an innovative partially latent
class model to attribute causes to pSBI.
Implications of all the available evidence
The list of causal bacteria we identified was long and diverse,
making prevention and treatment strategies complex.
Respiratory syncytial virus was the leading causal organism in
our study, suggesting an opportunity to develop
interventions based on maternal immunisation and provision
of monoclonal antibodies to neonates. Ureaplasma spp had
the second leading causal proportion, but have not previously
been recognised as common except in very preterm babies,
and are not targeted by current recommended antibiotic
regimens. Research into the epidemiology and pathogenesis
of this group of bacteria in neonates is needed. Despite
testing of blood and respiratory samples, for 72% of pSBI
episodes, no cause could be attributed. Use of metagenomics
approaches, minimally invasive tissue sampling, or both, to
investigate causes, with consideration of factors unrelated to
infections might facilitate appropriate decisions and
investments to save lives among very young babies, limit
unnecessary antibiotic use, and curb the emergence of
antimicrobial resistance in the community.

62 respiratory samples and found a high burden of viral
infections (48%).14
Ascertainment of the causes of pSBI has been hindered
by several factors: difficulty in case finding (ie, many
babies born at home die soon after birth without entering
the formal health system); insufficient availability of
diagnostic tools to detect bacterial and viral causes;
collection of blood samples with inadequate volume,
frequent contamination of blood cultures, or both; lack of
parallel samples from healthy controls and assessments
by sensitive molecular methods to provide information
on background colonisation by pSBI pathogens; and
absence of appropriate analytical approaches to use
information from multiple types of tests and samples to
attribute cause. To address these gaps in knowledge, we
did the Aetiology of Neonatal Infections in South Asia
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(ANISA) study in three countries (Bangladesh, India,
and Pakistan) to investigate the incidence of pSBI
episodes in the first 2 months of life and estimate the
proportions of bacterial and viral causes.

Methods

Study design and participants
ANISA was an observational cohort study done in
five sites in three countries. Four sites were rural (Sylhet,
Bangladesh; Matiari, Pakistan; and Vellore and Odisha,
India) and one was urban (Karachi, Pakistan). These sites
covered a total population of around 1·6 million people,
including roughly 250 000 married girls and women of
reproductive age (13–49 years) and around 30 000 births
per year.15 Eligible participants were married women of
reproductive age and live babies that could be enrolled up
to age 7 days.
We obtained informed verbal consent from pregnant
girls and women when they were registered in the study
and written informed consent when samples were
collected from babies. The study was approved by the
ethics committees or internal review boards of all
participating organisations.

Community-based surveillance
We recruited community health workers (CHWs) from
the local area through open advertisements. CHWs
established active community-based surveillance for
pregnancy, pregnancy outcomes, and signs of illness in
neonates. Briefly, they followed up married girls and
women of reproductive age by home visits to identify
pregnancies. They recorded dates of last menstrual
period, facilitated or encouraged accessing of antenatal
care, built rapport, and arranged visits to assess neo
nates immediately after birth. Live neonates visited by
CHWs within 7 days of birth were registered in the
study and scheduled for up to ten home visits up to age
59 days, three week 1 and one per week thereafter.
CHWs also collected socioeconomic, household, and
maternal information at enrolment and information on
labour and delivery at the first visit after birth.
Babies were assessed at every visit for signs of illness,
defined as respiratory rate 60 breaths per min or more,
severe chest in-drawing, hypothermia (temperature
<35·5°C), hyperthermia (temperature ≥38·0°C),
movement only with stimulation, convulsions, and poor
feeding as reported by the mother and confirmed by
CHW assessment.15 Babies with one or more signs of
pSBI were referred by the CHWs to study-designated
health-care facilities or visited at home by a study
physician (only in Matiari, Pakistan). To capture illness
episodes that occurred between visits, family members
were encouraged to seek assessment at a study health
facility or via the outreach physician (in Matiari). Ill
babies in Bangladesh and Pakistan were examined and
managed at primary care facilities or, if they had severe
or complicated illness, were referred to tertiary-level

hospitals. All ill babies in India were assessed and
managed at tertiary-level hospitals.

Collection of samples
Sample collection has previously been described in
detail.16 Briefly, trained phlebotomists followed standard
ised protocols to collect up to 3 mL blood from babies
with pSBI episodes for culture and molecular testing.
1 mL blood samples were taken from healthy controls for
molecular testing. Strict procedures to minimise
contamination during phlebotomy were followed: use of
sterile hand gloves and disposible dignity sheets for
babies; regular cleaning of the phlebotomy room with
disinfectant; and systematic use of antiseptic (alcohol
and iodine). Physicians used flocked swabs (Copan
Diagnostics, Brescia, Italy) to collect naso
pharyngeal
and oro
pharyngeal samples at the health centre from
symptomatic babies who met the criteria for pSBI and
from healthy babies when scheduled by the study team.
To characterise the background presence of potential
pSBI pathogens in the community, we used an automated
algorithm triggered by CHWs at the first postnatal visit to
select randomly registered healthy babies for collection of
samples. These babies were assigned an age at which to
undergo clinical assessment and sample collection, with
assignment probability based on the age distribution of
babies with pSBI episodes enrolled to that point.

Processing of samples
We used automated blood culture (culture media
BacTec, BD, Franklin Lakes, NJ, USA or BacT/Alert,
Biomérieux, Basinstoke, UK) to isolate bacterial
pathogens. Molecular testing was done by PCR
with Custom TaqMan Array Cards (Thermo Fisher,
Bartlesville, OK, USA) and LifeTech Viia 7 software
version 1.2.4 to detect 15 bacterial and 13 viral
pathogens.15,17 Bacterial strains from the cultures were
identified with a conventional biochemical test and the
API 20E strip test (bioMérieux-Vitek, Hazelwood, MO,
USA), and were confirmed at the Centers for Disease
Control and Prevention by matrix-assisted laser
desorption/ionisation-time of flight mass spectrometry.18
Antimicrobial susceptibility testing was done by disc
diffusion, in accordance with Clinical and Laboratory
Standards Institute guidelines. We used a MagNA Pure
LC total nucleic acid isolation kit (Roche, Basel,
Switzerland) to extract nucleic acid from blood samples
and nasopharyngeal and oropharyngeal swabs for
assessment.
Three infectious disease specialists reviewed and
classified each isolate as a pathogen or as not clinically
relevant, based on the clinical features of the patient, drug
susceptibility, illness management, and outcome.19 10% of
molecular samples were retested at the Centers for
Disease Control and Prevention to provide quality control
and assurance for site results (appendix). As an additional
assessment, we used real-time PCR for speciation of
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Bordetella spp and Ureaplasma spp and confirmation of
Escherichia coli positivity.

Definition of pSBI episodes
We defined confirmed pSBI episodes as the presence
of one sign of illness assessed by the CHWs, no
hospital admission in the preceding 7 days (except for
postnatal hospital stays for babies born in health
facilities), and no registered pSBI episode in the
preceding 7 days. We excluded babies with increased
respiratory rate as the only sign because, during the
study period, independent evidence showed low
specificity for this sign alone20 and samples were not
collected in several sites. Test results for samples from
healthy babies were included if the criteria for pSBI
were not met on the day of assessment or in the
previous 7 days before and after sample collection.

Statistical analysis
We aimed to enrol 400 healthy babies in each site in
Bangladesh and Pakistan and 200 in each Indian site.21
The sample size was constrained by ethical and
community acceptability, but we calculated that the
target sample size would be sufficient to provide initial
estimation of background colonisation with set falsepositive rates (appendix) and a maximum SE of 3%.
The primary objective was to estimate the proportion
of pSBI episodes attributed to each pathogen assessed.
Because the study design included two types of sample
(blood and respiratory), up to three tests per pathogen
(blood culture, blood molecular assay, and respiratory
molecular assay), and because each of these tests had
its own sensitivity and specificity for detection of the
true cause of the pSBI episode, we used a partially
latent class model, which was originally developed for a
similarly designed study of the causes of pneumonia22
and adapted to meet the ANISA study specifications
(appendix). For all babies with pSBI episodes and
healthy babies with at least one laboratory test result,
we included blood culture final determination data (for
those with pSBI episodes) and observed binary
molecular assay results (positive or negative) in the
model input dataset. We attributed causal proportions
to 28 target pathogens and two additional classes: other
blood culture (all organisms isolated from blood
cultures that did not have an associated pathogenspecific molecular assay test) and other or none
(episodes that could not be attributed to any pathogens).
The primary output of the model was mean pathogen
proportions at the population level with 95% credible
intervals (CrIs), from which individual-level proportions
could be derived (appendix). Covariates were study site,
age at onset, date of enrolment, and outcome status (died
but had a sample available from the previous 7 days vs
alive, except for Vellore, where there were too few deaths
to stratify by outcome). We ran the model under various
input dataset conditions, for which performance was
148

assessed by simulation studies (appendix). Model
convergence was assessed through trace and other
diagnosis plots. We assessed model assumptions with
interim model outputs by stopping the Gibbs sampler at
random cycles. Model fit to input data was evaluated by
comparing the fitted and observed numbers of positives
for each blood molecular assay and blood culture. We did
programming and computation with R (version 3.2.5),
SAS (version 9.3), and Stata (version 13).

Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report. The corresponding author had access to all
data in the study and had responsibility for the decision
to submit for publication.

Results
During surveillance, pregnancy outcome data were
collected for 74 145 (87%) of 84 971 pregnancies. 71 361 were
livebirths, 2324 were stillbirths, and 1283 were mis
carriages. 63 114 (88%) liveborn babies were registered and
followed up for 59 days, and the remaining 8247 babies
could not be reached within 7 days, due to death, migration
out of the area, or refusal to participate in the study
(figure 1, appendix). 56 960 (90%) liveborn neonates
were recruited within 72 h. Population character
istics,
in particular socioeconomic status, home delivery, preg
nancy outcomes, and early death among babies, varied by
site (table 1). 43 665 (69%) registered babies received all
three visits in the first week, and 48 415 (77%) received at
least eight of ten scheduled visits by CHWs. These visits
resulted in 12 836 referrals for clinical assessment by
physicians, of which 10 809 (84%) were attended.
Caregivers made 3683 additional self-referrals.
Physicians identified 6022 pSBI episodes, including
2498 early-onset (<3 days) and 3524 late-onset episodes
(3–59 days). 289 (5%) babies had more than one episode
(figure 1, table 2, appendix). The overall pSBI incidence
was 95·4 episodes per 1000 livebirths (range 78·3 per
1000 in Vellore, India, to 112·6 per 1000 in Karachi,
Pakistan) and was notably higher in the first 3 days of life
than in the remaining follow-up period (55·8 per
1000 livebirths vs 39·6 per 1000 livebirths), which is
equivalent to an increase in incidence density rate of
roughly 13·5 times.
Blood samples were collected from 4859 (81%) of
6022 babies during pSBI episodes, of which all were tested
by blood culture and 4216 (70%) were tested by molecular
assay (figure 1). 602 (10%) babies had received antibiotics
before blood samples were collected, mainly in Matiari,
Pakistan (439 [73%]). Molecular test results for respiratory
samples were available for 5209 (87%) of 6022 babies with
pSBI episodes. We also collected 1726 blood samples
(results available for 1717) and 1893 respiratory samples
from 1895 healthy babies for molecular testing (figure 1).
Healthy babies were older than sick children at the time of
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sample collection (median age 13·4 days, IQR 2·8–33·8 vs
5·7 days, 1·4–27·4) and cumulative enrolment of controls
did not always track pSBI episodes (appendix).
Of 4859 pSBI blood cultures, 338 (7%) yielded bacteria,
of which 206 were judged not to be clinically relevant
based on predefined criteria, 30 not to be clinically
relevant by an independent review panel, and 102 to be
clinically relevant. The incidence of culture-confirmed
infection was 1·6 per 1000 livebirths. Causal organisms
in blood cultures were predominately E coli, Klebsiella spp,
Staphylococcus aureus, and group A streptococcus. More
than half of causal bacteria were Gram negative, led by
Klebsiella spp and E coli (table 3), and incidence of Gramnegative organisms was higher among hospital-born
babies than in community-born babies (1·3 per
1000 livebirths vs 0·7 per 1000 livebirths). Most isolates
were susceptible to penicillin, ampicillin, gentamicin, or
a combination of these drugs (table 3). Isolates were
more susceptible to gentamicin (75 [74%]) than ampicillin
or penicillin (27 [41%]).
Among pSBI blood samples tested by molecular assay,
487 (12%) of 4216 tested positive for at least one target,
led by enterovirus or rhinovirus, Salmonella spp, Klebsiella
spp, and E coli, and 57 (1%) were positive for multiple
targets. Among 5209 respiratory samples 3907 (75%) were
positive for at least one target and 1302 (47%) were
positive for multiple targets (table 4). The numbers
of positive results were similar for blood and respiratory
samples from healthy babies, with some variation by site,
age, and outcome (table 4, appendix). Pathogens were
more prevalent among babies with pSBI than among
healthy babies, including for respiratory syncytial virus
and Ureaplasma spp (table 4). Among 566 samples
containing Ureaplasma spp, 311 (55%) were U parvum,
255 (45%) were U urealyticum, and the remainder
contained both species. Bordetella spp were detected in
similar proportions of babies with pSBI and healthy
babies, with most samples containing these species seen
in Karachi, Pakistan (table 4). Speciation of Bordetella spp
revealed that 84 (36%) of 234 samples from babies with
pSBI and 30 (41%) of 73 from healthy babies contained
B pertussis.
The estimated test-specific true-positive and false-positive
rates underlying the model-based proportions of causal
organisms and the estimated incidence are shown in the
appendix. Overall, 16% and 12% of pSBI episodes were
attributed to bacteria and viruses, respectively, and the
remaining 72% could not be attributed to any of the tested
pathogens. The leading pathogen was respiratory syncytial
virus, seen in 6·5% of cases (95% CrI 5·8–7·6), followed by
Ureaplasma spp, seen in 2·8% (1·9–3·8; figure 2). Klebsiella
pneumoniae, E coli, enterovirus or rhinovirus, Salmonella
spp, Streptococcus pneumoniae, group B streptococcus, and
S aureus were each attributed as the causal agent in more
than 1·0% of pSBI episodes (figure 2). Attribution of cause
to a specific pathogen was less likely among early-onset
than among late-onset episodes (22·5%, 95% CrI

Data collected during 84 971 pregnancies

10 826 pregnancy outcome unknown
4944 not assessed within 59 days of birth
3323 migrated out of area
2030 lost to follow-up
487 refused to participate
42 died before delivery

74 145 pregnancies with known outcomes

3607 non-livebirths
2324 stillbirths
1283 miscarriages

71 361 livebirths

8247 babies not enrolled in the study
6783 age >7 days
1284 baby died
111 baby/family moved
10 refused to participate
59 unknown/lost to follow-up

63 114 babies enrolled in the study

49 096 babies not assessed for pSBI
40 839 not referred by CHW
8257 referred by CHW but not assessed

14 018 babies assessed by physicians
(15 304 assessments)

7012 no pSBI signs

8292 pSBI signs

2351 not eligible for samples
2332 clinical signs within 7 days
6 hospitalised within 7 days
13 died within 7 days
2300 not previously selected for control

2270 excluded
2143 excluded due to fast
breathing only
127 admitted to hospital in
previous 7 days

6022 pSBI episodes

2361 eligible for samples

466 no samples

769 no samples

1895 healthy babies with samples

5253 babies with pSBI episodes
and samples

1893 respiratory samples tested by
molecular assay
1717 blood samples tested by
molecular assay

5209 respiratory samples tested
by molecular assay
4216 blood samples tested by
molecular assay
4859 blood samples tested by
culture

Figure 1: Study flow diagram
pSBI=possible serious bacterial infection. CHW=community health worker.
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19·2–26·0 vs 33·1%, 29·8–36·8). Furthermore, among
early-onset episodes, bacterial attributions were much
more frequent than viral (18·4% vs 4·1%; figure 2).

Ureaplasma spp were the most frequent causal organisms,
with an estimated pathogen proportion of 3·1% (95% CrI
1·9–4·4). E coli, K pneumoniae, group B streptococcus,

Sylhet

Karachi

Matiari

Odisha

Vellore

22 426

17 700

19 251

8424

6344

Total

Maternal
All
Age at delivery (years)

26 (13–53)

First birth

6678 (32%)

26 (13–55)
3619 (25%)

29 (13–54)
3414 (22%)

25 (14–49)
4050 (51%)

24 (14–44)

74 145
27 (13–55)

2724 (50%)

20 485 (28%)

Stillbirths (per 1000 pregnancies with known
outcome)

35·3

30·1

39·0

19·2

9·9

31·0

Miscarriages/spontaneous abortion (per
1000 pregnancies with known outcome)

12·9

28·2

18·1

6·3

14·5

17·3

Poor nutritional status*

3677 (16%)

1133 (7%)

1351 (7%)

774 (9%)

374 (6%)

Received full antenatal package†

6778 (64%)

6973 (57%)

5729 (42%)

6041 (93%)

4319 (68%)

29 840 (40%)

13 518 (99%)

12 878 (95%)

16124 (99%)

7912 (98%)

6326 (100%)

56 758 (77%)

At least one antenatal care visit with a skilled
provider

7309 (10%)

Birth location
Health facility

3744 (17%)

9709 (56%)

12 502 (66%)

8001 (96%)

6230 (100%)

40 186 (54%)

18 322 (83%)

7478 (43%)

6379 (34%)

368 ( 4%)

21 (<1%)

32 568 (44%)

Skilled birth attendant‡

4355 (20%)

10 381 (60%)

12 410 (66%)

78 04 (93%)

6234 (100%)

41 184 (56%)

Clean delivery kit

2814 (13%)

13 358 (78%)

13 133 (69%)

7536 (90%)

6112 (98%)

42 953 (58%)

17 223 (77%)

8375 (49%)

3340 (17%)

6856 (81%)

6227 (98%)

42 021 (57%)

6 (1–35)

8 (1–35)

7 (1–35)

5 (1–31)

4 (2–29)

6 (1–35)

10 127 (45%)

16 763 (99%)

17 373 (90%)

6945 (82%)

6315 (100%)

57 523 (78%)

Home

Ever attended school/madrasa
Household members
Electricity
Piped water

271 ( 1%)

Mobile phone ownership

10 677 (63%)

5667 (29%)

1235 (15%)

5414 (85%)

23 264 (31%)

18 373 (82%)

13 069 (77%)

14 123 (73%)

7245 (86%)

6006 (95%)

58 816 (80%)

19 007

13 321

16 462

8197

6127

63 114

Babies
All
Age at registration (h)

6 (0–60)

Child-days observed (in 10 000 days)
Boys/girls

101·6
9669 (51%)/9338
(49%)

20 (0–162)

18 (0–159)

57·5

76·6

6812 (51%)/6509
(49%)

8516 (52%)/7946
(48%)

7 (0–156)
43·2
4247 (52%)/3950
(48%)

7 (0–143)
34·4
3175 (52%)/2952
(48%)

12 (0–162)
313·5
32 419 (51%)/30 695
(49%)

Preterm

3336 (18%)

2485 (20%)

4882 (30%)

1341 (17%)

431 (7%)

12 475 (20%)

Low birthweight

5153 (27%)

3116 (24%)

6191 (38%)

1593 (19%)

779 (13%)

16 832 (27%)

Massage after birth

3053 (16%)

6249 (47%)

11 379 (69%)

2023 (25%)

Washed after birth

2613 (14%)

12 634 (95%)

16 130 (98%)

6411 (78%)

3922 (64%)

41 710 (66%)

3711 (22%)

6817 (37%)

1378 (17%)

6034 (97%)

18 920 (27%)

Proper cord care at birth§

980 (5%)

Age at breastmilk supplementation (days)¶
Ever vaccinated (assessed at day 59 visit)

35 (0–62)
6790/16 261 (42%)

4 (0–65)

6 (0–65)

4 (0–60)

5035/82 00 (61%)

4466/6563 (68%)

6581/7064 (93%)

0

27 (0–65)
5767/5814 (99%)

22 704 (36%)

18 (0–35)
28 639/43 902 (65%)

BCG

4003 (59%)

3916 (78%)

4466 (100%)

5960 (91%)

5474 (95%)

At least one oral polio vaccine

1937 (29%)

3439 (68%)

3845 (86%)

4930 (75%)

5461 (95%)

19 612 (68%)

Diphtheria, tetanus, and pertussis toxin

1430 (22%)

904 (18%)

1829 (41%)

3671 (56%)

5053 (88%)

12 887 (45%)

50 (1%)

119 (2%)

Pneumococcal conjugate vaccine

2 (<1%)

113 (2%)

20 (<1%)

23 819 (83%)

304 (1%)

Mean early onset of infection per 1000 livebirths
(95% CI)

33·0 (30·5–35·7)

51·8 (48·1–55·9)

44·3 (41·2–47·7)

25·7 (22·5–29·5)

38·8 (34·2–44·1)

39·6 (38·1–41·2)

Mean late onset of infection per 1000 livebirths
(95% CI)

53·7 (50·5–57·1)

60·7 (56·7–65·1)

51·1 (47·8–54·7)

74·4 (68·7–80·5)

39·4 (34·8–44·8)

55·8 (54·0–57·7)

Mean mortality among babies younger than
60 days per 1000 livebirths (95% CI)

46 (44–48)

48 (45–52)

57 (54–61)

17 (14–20)

11 (8–14)

43 (41–45)

Data are median, median (range), or n (%), unless stated otherwise. Variables with ≥10% missing data were number of antenatal care visits (28%), first birth (13%), and materials used to cut and tie the umbilical
cord (13%). *Defined as mid-upper-arm circumference <21·5 cm. †Receipt of at least two antenatal visits from a community health worker with receipt of two tetanus injections during current pregnancy, one
tetanus injection and at least four shots before pregnancy, or at least five tetanus injections before pregnancy, and receipt of at least one iron tablet or dose of iron syrup during current pregnancy. ‡Qualified
doctor, nurse, midwife, or paramedic. §For cutting, boiled thread, clip kit, knife, blade, or tongs in the home or nurse’s or doctor’s scissor or clip kit in a hospital or health facility; for tying, boiled clip, clip kit, thin
rope brought by doctor, blade, or rubber band followed by application of antibiotic or antiseptic to the stump in the home, and clip or clip kit followed by application of antibiotic, antiseptic, or nothing in the
hospital of health facility. ¶Age at which any food or liquid other than breastmilk was first given to the baby.

Table 1: Characteristics of mothers with a birth outcome and of registered liveborn babies
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Sylhet

Karachi

Matiari

1540

1401

1481

Odisha

Vellore

Total

446

5650

Maternal
All
Age

26 (14–53)

First livebirth
Ever attended school/madrasa
At least one antenatal care visit with skilled provider

543 (35%)

26 (14–52)
340 (24%)

30 (15–54)

782
24 (15–43)

354 (24%)

421 (54%)

24 (16–39)
275 (62%)

27 (14–54)
1933 (34%)

1106 (72%)

603 (44%)

191 (13%)

643 (82%)

436 (98%)

2979 (53%)

832 (54%)

1009 (72%)

1258 (85%)

738 (94%)

446 (100%)

4283 (76%)

Birth location
Health facility

164 (11%)

717 (51%)

957 (65%)

753 (96%)

444 (100%)

3029 (54%)

1376 (89%)

684 (49%)

524 (35%)

29 ( 4%)

2 (<1%)

2610 (46%)

Skilled birth attendant*

216 (14%)

775 (55%)

945 (64%)

726 (93%)

444 (100%)

3106 (55%)

Clean delivery kit

159 (10%)

1083 (77%)

1015 (68%)

706 (90%)

437 (98%)

3400 (60%)

6 (2–27)

8 (2–35)

7 (2–35)

5 (2–24)

4 (2–19)

6 (2–35)

Home

Household members
Babies
All

1561

Boys/girls

909 (58%)

1416

1491

785 (55%)

808 (54%)

790

455

5713

467 (59%)

272 (60%)

3241 (57%)

Preterm

447 (29%)

361 (27%)

499 (34%)

182 (23%)

75 (17%)

1564 (28%)

Low birthweight

619 (43%)

455 (36%)

605 (45%)

230 (30%)

93 (21%)

2002 (38%)

Ever vaccinated (assessed at day 59 visit)

494/1151 (43%)

462/818 (56%)

528/1051 (50%)

627/685 (92%)

426/433 (98%)

2537/4138 (61%)

BCG

279 (24%)

345 (42%)

365 (35%)

578 (84%)

405 (94%)

1972 (48%)

At least one oral polio vaccine

207 (18%)

298 (36%)

310 (30%)

508 (74%)

406 (94%)

1729 (42%)

Diphtheria, tetanus, and pertussis toxin

105 (9%)

72 (9%)

135 (13%)

369 (54%)

355 (82%)

1036 (25%)

Pneumococcal conjugate vaccine
Possible serious bacterial infection episodes
Early onset (age <3 days)

3 (<1%)
1649

7 (1%)
1500

0
1572

10 (2%)

2 (1%)

22 (1%)

821

480

6022

730 (46%)

211 (26%)

238 (50%)

2498 (42%)

628 (38%)

691 (46%)

Respiratory rate ≥60 breaths per min

756 (46%)

600 (40%)

681 (43%)

175 (21%)

98 (20%)

2310 (38%)

Severe chest in-drawing

602 (37%)

385 (26%)

290 (18%)

58 (7%)

83 (17%)

1418 (24%)

Integrated management of childhood infection signs

Axillary temperature ≥38·0°C

326 (20%)

467 (31%)

789 (50%)

372 (45%)

96 (20%)

2050 (34%)

Axillary temperature <35·5°C

284 (17%)

196 (13%)

182 (12%)

27 (3%)

8 (2%)

697 (12%)

Movement only when stimulated or no movement

299 (18%)

164 (11%)

161 (10%)

223 (27%)

72 (15%)

919 (15%)

Convulsions (observed or in history)

306 (19%)

88 ( 6%)

299 (19%)

65 (8%)

17 (4%)

775 (13%)

Poor feeding (confirmed by observation)

702 (43%)

557 (37%)

363 (23%)

596 (73%)

301 (63%)

2519 (42%)

1090 (66%)

769 (51%)

904 (58%)

476 (58%)

157 (33%)

3396 (56%)

More than one sign
Other clinical signs
Umbilical flare or infection

28 (2%)

20 (1%)

43 (3%)

12 (3%)

22 (3%)

125 (2%)

Nappy rash or skin pustules

83 (5%)

98 (7%)

69 (4%)

102 (12%)

28 (6%)

380 (6%)

Conjunctivitis

54 (3%)

7 (<1%)

12 (1%)

29 (4%)

5 (1%)

107 (2%)

Bulging fontanelle

13 (1%)

2 (<1%)

27 (2%)

7 (1%)

1 (<1%)

Hospital admission

417 (25%)

193 (13%)

129 (8%)

563 (69%)

441 (92%)

1743 (29%)

307 (19%)

169 (11%)

220 (14%)

52 (6%)

15 (3%)

763 (13%)

239 (15%)

116 (8%)

149 (10%)

40 (5%)

8 (2%)

552 (9%)

Death
Within 7 days of episode

50 (1%)

Data are n, n(%), or median (IQR). *Qualified doctor, nurse, midwife, or paramedic.

Table 2: Characteristics of possible serious bacterial infection episodes

Salmonella spp, S aureus, and respiratory syncytial virus all
had proportion point estimates greater than 1·0% (figure 2).
Among late-onset episodes, the proportion attributed to
viruses was 16·5%, similar to that attributed to bacteria
(16·6%) and were predominantly respiratory syncytial
virus (9·1%, 95% CrI 7·7–10·9) and Ureaplasma spp
(2·5%, 1·6–3·4; figure 2). Attribution of bacterial causes
differed by site: the leading bacterial causes were
S pneumoniae in Sylhet (2·6% of episodes, 95% CrI

1·4–4·7), Ureaplasma spp in Matiari (5·3%, 3·0–7·4), and
Klebsiella spp in Odisha (7·2%, 4·4–7·2; figure 2).
Respiratory syncytial virus was the leading viral cause in all
sites (figure 2).
The overall incidence of bacterial infections was
13·2 (95% CrI 11·2–15·6) per 1000 livebirths (table 5).
For Ureaplasma spp, the overall incidence was
2·4 (95% CrI 1·6–3·2) per 1000 livebirths, with the
highest incidence seen in Matiari. K pneumoniae was the
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152

0

0

3 (60%)

1

5

Streptococcus oralis

Streptococcus
pneumoniae

2 (66%)

3

Serratia marcescens

51 (50%)/51 (50%)

2 (66%)/1 (33%)

1 (50%)/1 (50%)

1 (33%)/2 (66%)

0/1 (100%)

3 (60%)/2 (40%)

0/1 (100%)

10 (59%)/7 (41%)

11 (52%)/10 (48%)

2 (66%)/1 (33%)

1 (100%)/0

0/1 (100%)

1 (50%)/1 (50%)

6 (100%)/0

38 (58%) /28 (42%)

2 (40%)/3 (60%)

1 (100%)/0

5 (42%)/7 (58%)

3 (50%)/3 (50%)

2 (18%)/9 (82%)

0

13 (36%)/23 (64%)

64 (63%)

3 (100%)

0

1 (33%)

0

1 (20%)

0

16 (94%)

16 (76%)

3 (100%)

0

1 (100%)

2 (100%)

4 (66%)

47 (71%)

0

0

10 (83%)

1 (17%)

5 (45%)

1 (100%)

17 (47%)

Hospital

38 (37%)

0

2 (100%)

2 (66%)

1 (100%)

4 (80%)

1 (100%)

1 (6%)

5 (24%)

0

1 (100%)

0

0

2 (33%)

19 (29%)

5 (100%)

1 (100%)

2 (17%)

5 (83%)

6 (55%)

0

19 (53%)

Home

Place of birth (%)

28 (27%)

2 (66%)

1 (50%)

1 (33%)

1 (100%)

1 (20%)

0

3 (18%)

10 (48%)

1 (33%)

0

0

0

1 (17%)

21 (32)

1 (20%)

0

2 (17%)

3 (50%)

1 (9%)

0

7 (19%)

Gestational
age
<37 weeks*

30 (29%)

2 (66%)

0

3 (100%)

0

0

1 (100%)

4 (24%)

11 (52%)

1 (33%)

0

0

0

1 (17%)

23 (35)

2 (40%)

1 (100%)

1 (8%)

2 (66%)

0

1 (100%)

7 (19%)

Died

27 (26%)

0

0

1 (33%)

0

4 (80%)

1 (100%)

1 (6%)

4 (19%)

0

1 (100%)

0

0

0

12 (18%)

4 (80%)

1 (100%)

1 (8%)

5 (83%)

4 (36%)

15 (42%)

Sylhet

Site

15 (15%)

1 (33%)

2 (100%)

0

1 (100%)

1 (20%)

0

2 (12%)

3 (14%)

1 (33%)

0

0

0

2 (33%)

13 (20)

0

0

0

0

2 (18%)

0

2 (6%)

Karachi

17 (17%)

0

0

2 (66%)

0

0

0

2 (12%)

3 (14%)

0

0

0

2 (100%)

1 (17%)

10 (15)

1 (20%)

0

2 (17%)

0

4 (36%)

0

7 (19%)

Matiari

10 (10%)

0

0

0

0

0

0

1 (6%)

3 (14%)

1 (33%)

0

0

0

0

5 (8%)

0

0

3 (25%)

1 (17%)

1 (9%)

0

5 (14%)

Vellore

33 (32%)

2 (66%)

0

0

0

0

0

11 (65%)

8 (38%)

1 (33%)

0

1 (100%)

0

3 (50%)

26 (39%)

0

0

6 (50%)

0

0

1 (100%)

7 (19%)

Odisha

85 (83%)

··

··

··

··

5 (100%)

··

13 (75%)

16 (75%)

··

··

··

··

3 (50%)

50 (75%)

5 (100%)

··

11 (92%)

6 (100%)

11 (100%)

··

35 (97%)

Susceptibility to
penicillin, ampicillin,
and/or gentamicin†

Table 3: Characteristics of clinically relevant bacteria isolated in blood cultures from babies with possible serious infections

*Two babies had missing values for gestational age. †WHO recommended treatment for neonatal sepsis at community level; individual percentages were calculated for the organisms associated with five or more episodes of infection. ‡A baumanii
(n=3), A lwoffii (n=2), A schindleri (n=1); and A baumanii isolated in a polymicrobial culture with Serratia marcescens. §E aerogenes (n=1) and E cloacae (n=2). ¶E coli found in two polymicrobial cultures (one with Enberobacter cloacae and one with
A baumanii). ||K pneumoniae (n=16); K terrigena (n=1); and K pneumoniae found in one polymicrobial culture with Pseudomonas aeruginosa. **N meningitidis found in one polymicrobial culture with Plesiomonas shigelloides. ††P aeruginosa (n=1);
P fluorescens (n=1); P pseudomallei (n=1).

34 (33%)

0

2

Salmonella enterica

102

1 (33%)

Total

1 (100%)

5

Neisseria meningitidis**

1

0

1

Morganella morganii

3

0

17

Proteus mirabilis

9 (43%)

6 (86%)

21

Escherichia coli¶

Klebsiella spp||

Pseudomonas spp††

0

0

1

1 (100%)

1

Citrobacter koseri

3

1 (50%)

2

Burkholderia cepacia

Edwardsiella tarda

3 (50%)

6

Enterobacter spp§

24 (36%)

66

Acinetobacter spp‡

All

Gram negative

6 (100%)

6

12

Staphylococcus aureus

1 (9%)

11

Group A streptococcus

Group B streptococcus

0

10 (28)

1

36

Age <72 h at Boys/ girls (%)
culture (%)

Enterococcus faecium

All

Gram positive

No.
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Nasopharyngeal or oropharyngeal
Positive babies with Positive healthy
symptoms (n=5209) babies (n=1893)

Blood
Odds ratio
(95% CI)

Positive babies with Positive healthy
symptoms (n=4216) babies (n=1717)

Odds ratio
(95% CI)

Bacteria
1·2 (0·9–1·5)

··

··

··

Chlamydia pneumoniae

11 (<1%)

3 (<1%)

1·3 (0·4–4·8)

··

··

··

Chlamydia trachomatis

12 (<1%)

5 (<1%)

0·9 (0·3–2·5)

··

··

1363 (26%)

461 (24%)

1·1 (1·0–1·2)

75 (2%)

32 (2%)

Bordetella spp

Escherichia coli

234 (5%)

73 (4%)

Group A streptococcus

··

··

Group B streptococcus

427 (8%)

123 (7%)

··

··

1149 (22%)

422 (22%)

10 (<1%)

1 (<1%)

Pan-Haemophilus influenzae
Klebsiella pneumoniae
Mycoplasma pneumoniae
Neisseria meningitidis

··

··

··
1·3 (1·0–1·6)
··
1·0 (0·9–1·1)

14 (<1%)

0

19 (1%)

6 (<1%)

1·3 (0·5–3·2)

36 (1%)

6 (<1%)

2·5 (1·0–5·8)

77 (2%)

3·6 (0·5–28·5)

··

··

··
1·0 (0·6–1·5)

7 (<1%)*

33 (2%)
··

1·0 (0·6–1·4)
··

4 (<1%)

0·7 (0·2–2·5)

7 (<1%)

1·1 (0·5–2·6)

Pseudomonas aeruginosa

··

··

··

19 (1%)

Salmonella spp

··

··

··

78 (2%)

30 (2%)

1·1 (0·7–1·6)

Staphylococcus aureus

··

··

··

29 (1%)

15 (1%)

0·8 (0·4–1·5)

1843 (35%)

628 (33%)

1·1 (1·0–1·2)

61 (2%)

20 (1%)

1·3 (0·8–2·1)

566 (11%)

118 (6%)

1·8 (1·5–2·3)

19 (1%)

Streptococcus pneumoniae
Ureaplasma spp

6 (<1%)

1·3 (0·5–3·2)

Viruses
Adenovirus
Cytomegalovirus
Enterovirus or rhinovirus

75 (1%)

34 (2%)

0·8 (0·5–1·2)

··

··

363 (8%)†

153 (9%)‡

0·9 (0·7–1·1)

··

··

1521 (29%)

644 (34%)

0·8 (0·7–0·9)

131 (3%)

49 (3%)

··
1·1 (0·8–1·5)

Human metapneumovirus

21 (<1%)

1·3 (0·5–3·2)

··

··

··

Human parechovirus

20 (<1%)

12 (1%)

0·6 (0·3–1·2)

··

··

··

Influenza type A

53 (1%)

13 (1%)

1·5 (0·8–2·7)

··

··

··

Influenza type B

31 (1%)

3 (<1%)

3·8 (1·2–12·4)

··

··

··

Parainfluenza 1

25 (1%)

7 (<1%)

1·3 (0·6–3·0)

··

··

··

7 (<1%)

0·4 (0·1–1·0)

··

··

··

Parainfluenza 2
Parainfluenza 3
Respiratory syncytial virus
Rubella

7 (<1%)

6 (<1%)

··

65 (1%)

16 (1%)

1·5 (0·9–2·6)

··

··

··

402 (8%)

25 (1%)

6·3 (4·2–9·4)

··

··

··

1·5 (0·6–3·9)

··

··

··

20 (<1%)

5 (<1%)

*Of 4195 tested. †Of 4751 tested. ‡Of 1800 tested.

Table 4: Detected pathogens among babies with possible serious infections and healthy babies

next leading pathogen, for which the highest incidence
was in Odisha. Incidence of E coli varied little across sites
and S aureus was a rare cause except in the Indian sites,
where incidence was greater than 2·0 per 1000 livebirths
(table 5).
The overall incidence of viral infections was
10·1 (95% CrI 9·4–11·6) per 1000 livebirths (range across
sites 5·5–15·7 per 1000 livebirths, table 5). The incidence
of respiratory syncytial virus was greater than 2·5 per
1000 livebirths in all sites, peaking in Sylhet
(7·3 infections per 1000 livebirths). For all other viruses,
the incidence was 1·1 per 1000 livebirths or lower, with
site-specific variations (table 5).
Overall, among 71 361 livebirths, 3061 (4%) babies died
before age 60 days (range 11 per 1000 livebirths in Vellore
to 57 per 1000 livebirths in Matiari; overall mortality
42·9 per 1000 livebirths). 1377 (45%) of these 3061 deaths
occurred among non-registered babies (1284 within
7 days and 93 after 7 days) and 1684 (55%) among

registered babies. Among 1377 babies who were not
visited by a CHW before death, 941 (68%) died within
24 h of birth (median age 6·1 h, appendix). Mortality
among registered babies was 26·7 deaths per
1000 livebirths, which was 7·4 (95% CrI 6·7–8·1) times
higher among babies with pSBI than among healthy
babies (125·0 vs 16·9 per 1000 livebirths). Among the
1684 registered babies who died, 689 (41%) were assessed
by a physician before death and pSBI was confirmed.
Samples were collected from 349 (49%) of these
confirmed episodes in the 7 days before death (appendix).
Among 102 babies with confirmed episodes who died
within 24 h of birth, 37 (36%) had samples collected.
Causal pathogen attributions were made in sub
stantially more babies with pSBI episodes who died than
among those who survived (46%, 95% CrI 37–56 vs 27%,
24–30). Of the deaths among babies with pSBI episodes
with attributed pathogens, 92% were due to bacteria, led
by E coli (causal proportion 8·7%, 95% CrI 5·2–13·4)
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A

Mean (95% CrI)

B

Early onset
Late onset

Early mean
(95% CrI)

Late mean
(95% CrI)

Bordetella spp

0·80 (0·41–1·58)

Bordetella spp

0·33 (0·03–1·02)

1·01 (0·45–1·92)

Chlamydia pneumoniae

0·09 (0·04–0·18)

Chlamydia pneumoniae

0·03 (0–0·10)

0·13 (0·01–0·32)

Chlamydia trachomatis

0·25 (0·14–0·49)

Chlamydia trachomatis

0·15 (0·01–0·39)

0·31 (0·10–0·66)

Escherichia coli

1·71 (1·05–2·62)

Escherichia coli

2·41 (1·60–3·45)

1·77 (1·11–2·72)

Group A streptococcus

0·30 (0·27–0·35)

Group A streptococcus

0·52 (0·33–0·74)

0·53 (0·38–0·70)

Group B streptococcus

1·12 (0·65–1·71)

Group B streptococcus

1·66 (0·91–2·62)

0·91 (0·48–1·43)

Klebsiella pneumoniae

1·79 (1·17–2·49)

Klebsiella pneumoniae

2·14 (1·42–2·94)

1·83 (1·17–2·62)

Mycoplasma pneumoniae

Mycoplasma pneumoniae

*

*

Neisseria meningitidis

0·19 (0·12–0·31)

Neisseria meningitidis

0·17 (0·07–0·32)

0·35 (0·18–0·59)

pan-Haemophilus influenzae

0·44 (0·25–0·93)

pan-Haemophilus influenzae

0·19 (0·02–0·50)

0·56 (0·22–1·25)

Pseudomonas aeruginosa

0·28 (0·13–0·62)

Pseudomonas aeruginosa

0·42 (0·10–0·99)

0·26 (0·06–0·62)

Salmonella spp

1·28 (0·53–2·52)

Salmonella spp

1·44 (0·49–2·98)

1·18 (0·46–2·30)

Staphyloccocus aureus

1·05 (0·63–1·68)

Staphyloccocus aureus

1·32 (0·78–2·11)

1·26 (0·80–1·93)

Streptococcus pneumoniae

1·15 (0·70–1·98)

Streptococcus pneumoniae

0·93 (0·49–1·61)

1·30 (0·69–2·38)

Ureaplasma spp

2·82 (1·93–3·77)

Ureaplasma spp

3·07 (1·85–4·43)

2·45 (1·57–3·44)

Other blood culture

2·57 (2·05–3·11)

Other blood culture

3·62 (2·77–4·37)

2·66 (2·09–3·31)

0·23 (0–0·68)

0·63 (0·28–1·19)

Adenovirus

0·50 (0·26–0·92)

Adenovirus

Cytomegalovirus

0·83 (0·36–1·53)

Cytomegalovirus

0·73 (0·23–1·42)

0·88 (0·31–1·93)

Enterovirus or rhinovirus

1·36 (0·83–2·37)

Enterovirus or rhinovirus

0·43 (0·16–0·85)

1·85 (0·99–3·37)

Human metapneumovirus

0·41 (0·27–0·73)

Human metapneumovirus

0·11 (0·01–0·31)

0·57 (0·25–1·06)

Human parechovirus

0·17 (0·09–0·33)

Human parechovirus

0·06 (0–0·18)

0·26 (0·06–0·57)

Influenza A

0·51 (0·24–0·94)

Influenza A

0·29 (0·07–0·65)

0·65 (0·24–1·30)

Influenza B

0·53 (0·38–0·92)

Influenza B

0·22 (0·06–0·49)

0·72 (0·36–1·31)

Parainfluenza virus type 1

0·49 (0·31–0·87)

Parainfluenza virus type 1

0·17 (0·03–0·38)

0·67 (0·31–1·27)

Parainfluenza virus type 2

0·07 (0·03–0·15)

Parainfluenza virus type 2

0·01 (0–0·04)

0·10 (0–0·29)

Parainfluenza virus type 3

0·70 (0·45–1·21)

Parainfluenza virus type 3

0·11 (0·01–0·30)

1·02 (0·55–1·83)

Respiratory syncytial virus

6·48 (5·81–7·59)

Respiratory syncytial virus

1·55 (1·11–2·06)

9·13 (7·73–10·89)

Rubella

0·14 (0·08–0·26)

Rubella

0·17 (0·03–0·39)

0·12 (0·03–0·26)
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Overall*

Sylhet

Karachi

Matiari

Vellore

Odisha

Bacteria†
13·24 (11·18–15·63)

10·38 (7·69–13·62)

Bordetella spp

All bacteria tested

0·66 (0·34–1·32)

0·19 (0·04–0·57)

13·18 (9·3–17·91)
1·48 (0·17–3·98)

11·43 (8·78–14·32)
0·14 (0·07–0·27)

10·61 (7·44–14·89)
0·3 (0·11–0·82)

23·46 (18·52–29·27)
1·63 (1·1–2·82)

Chlamydia pneumoniae

0·07 (0·04–0·15)

0·29 (0·14–0·58)

0

0

0

0
0

Chlamydia trachomatis

0·21 (0·12–0·41)

0·48 (0·25–0·96)

0

0·33 (0·14–0·7)

0

Escherichia coli

1·43 (0·88–2·18)

1·21 (0·6–2·11)

1·68 (0·65–2·94)

0·86 (0·43–1·42)

1·42 (0·58–2·89)

2·49 (1·46–4·4)

Group A streptococcus

0·25 (0·23–0·29)

0·28 (0·24–0·38)

0·25 (0·22–0·33)

0·36 (0·31–0·47)

0·25 (0·24–0·4)

0

Group B streptococcus

0·93 (0·54–1·43)

1·36 (0·65–2·4)

0·28 (0·12–0·62)

0·97 (0·45–1·61)

1·99 (0·78–4·01)

0·16 (0·1–0·5)

Pan-Haemophilus influenzae

0·38 (0·21–0·79)

0

0·69 (0·35–1·52)

0·57 (0·26–1·29)

0

0·53 (0·08–1·49)
6·99 (4·27–9·99)

Klebsiella pneumoniae

1·49 (0·97–2·06)

0·36 (0·15–0·83)

0·52 (0·28–0·96)

0·46 (0·22–0·89)

0·87 (0·34–2·11)

Mycoplasma pneumoniae

0 (0–0)

0

0

0

0

0

Neisseria meningitidis

0·15 (0·1–0·26)

0·44 (0·26–0·79)

0·2 (0·15–0·35)

0

0

0

Pseudomonas aeruginosa

0·24 (0·11–0·52)

0

0

0·17 (0·08–0·47)

1·14 (0·5–2·8)

0·35 (0·14–1·23)

Salmonella spp

1·07 (0·44–2·11)

1·12 (0·06–2·73)

2·46 (0·9–4·69)

0·61 (0·11–2·28)

0·39 (0·11–1·46)

0·54 (0·12–1·64)

Staphylococcus aureus

0·88 (0·53–1·4)

0·25 (0·12–0·62)

0

0·57 (0·25–1·1)

2·49 (1·22–4·51)

2·35 (1·26–3·95)

Streptococcus pneumoniae

0·96 (0·58–1·64)

1·85 (1·01–3·41)

0·51 (0·19–1·2)

0·77 (0·37–1·46)

0·17 (0·09–0·44)

0·99 (0·26–2·25)

Ureaplasma spp

2·38 (1·62–3·17)

1·32 (0·42–2·79)

2·32 (1·16–3·9)

4·34 (2·49–6·1)

0·62 (0·14–1·88)

2·1 (0·69–4·27)

Other in blood culture‡

2·14 (1·71–2·6)

1·24 (0·87–1·66)

2·81 (1·87–3·95)

1·27 (0·94–1·75)

0·97 (0·66–1·37)

5·3 (3·91–6·9)

10·13 (9·04–11·55)

15·68 (13·41–18·52)

Viruses†
8·7 (7·14–10·78)

5·46 (4·29–6·87)

9·31 (7·75–11·25)

Adenovirus

All viruses tested

0·42 (0·22–0·77)

0·56 (0·13–1·16)

1·06 (0·47–2·21)

0·24 (0·06–0·59)

0

11·81 (8·68–15·35)
0

Cytomegalovirus

0·69 (0·3–1·27)

0·82 (0·05–2·67)

0·19 (0·05–0·62)

0·36 (0·04–1·07)

1·82 (0·67–2·88)

0·82 (0·08–2·84)

Enterovirus or rhinovirus

1·12 (0·69–1·96)

2·37 (1·4–4·02)

0·41 (0·11–1·4)

0·71 (0·23–1·39)

0·66 (0·14–1·73)

1·09 (0·21–3·18)

Human metapneumovirus

0·34 (0·22–0·61)

0·72 (0·45–1·31)

0·56 (0·3–1·1)

0

0·4 (0·16–0·99)

0

Human parechovirus

0·14 (0·07–0·27)

0·24 (0·06–0·55)

0

0

0

0·52 (0·37–1·06)

Influenza type A

0·42 (0·2–0·78)

0·89 (0·32–1·77)

0·47 (0·09–1·05)

0·19 (0·06–0·57)

0

0·34 (0·07–1·21)

Influenza type B

0·44 (0·31–0·76)

0·86 (0·6–1·51)

0·18 (0·07–0·59)

0·27 (0·11–0·55)

0

0·72 (0·56–1·41)

Parainfluenza 1

0·41 (0·26–0·72)

0·43 (0·19–0·82)

0·32 (0·06–0·69)

0·37 (0·15–0·78)

0

0·89 (0·52–1·79)

Parainfluenza 2

0·06 (0·03–0·13)

0·14 (0·05–0·38)

0 (0–0)

0·07 (0·06–0·17)

0

0 (0–0)

Parainfluenza 3

0·58 (0·37–1·01)

1·33 (0·96–2·28)

0·62 (0·11–1·3)

0·18 (0·05–0·38)

0·36 (0·1–0·84)

0·19 (0·07–0·8)

Respiratory syncytial virus

5·39 (4·84–6·31)

7·32 (6·45–8·56)

4·9 (4·28–5·79)

2·63 (1·94–3·32)

6·06 (5·25–7·23)

7·24 (4·88–9·3)

Rubella

0·12 (0·07–0·23)

0

0

0·43 (0·25–0·82)

0

0

Other or none§

60·42 (57·69–62·87)

46·18 (41·95–49·84)

72·18 (67·35–76·43)

65·18 (61·89–68·16)

58·26 (53·75–62)

61·95 (55·16–67·73)

Data are means with 95% credible intervals. *Aggregated incidence was calculated by weighting site-specific incidence estimates by average registered livebirths per month. †Rates are based on the estimated
pathogen prevalence among possible serious bacterial infection episodes, derived from the partially latent class model used to assess 5253 episodes identified among 63 114 registered livebirths. ‡Includes all
bacteria that grew on blood culture but did not have an associated assay on the ANISA molecular diagnostic panel, and which were estimated indirectly by calculating the product of the number of blood culture
isolates in this class and the average estimated causal proportion attributed to pathogens with multiple tests that included blood culture. §Includes any episode of possible serious bacterial infection not
attributed by the partially latent class model to one of the ANISA pathogen classes.

Table 5: Estimated cause-specific incidence per 1000 livebirths, based on results of a partially latent class model

and Ureaplasma spp (8·3%, 4·1–12·3; figure 3). Other
pathogens that were over-represented among babies
with pSBI who died compared with among those who
survived were K pneumoniae, S pneumoniae, group B
streptococcus, and Pseudomonas aeruginosa (figure 3).
In contrast, the proportion attributed to respiratory
syncytial virus was greater among babies who died than

Figure 2: Attributed proportions of causal pathogens tested during possible
serious bacterial infection episodes, estimated in a partially latent class
model
(A) Estimates from overall model. (B) Estimates by age of onset. (C) Estimates of
bacterial causes by study site. (D) Estimates of viral causes by study site.
CrI=credible interval. pSBI=possible serious bacterial infection. *None detected.

among those who survived (2·1%, 95% CrI 1·3–3·2 vs
6·7%, 5·9–7·8).
Given these differences in pathogen distributions
between babies who died and those who survived and
the low capture of samples within 7 days of life
(11·6% of deaths), we did a sensitivity analysis to
ascertain the potential effect on the overall distribution
of causal organisms. Specifically, we assumed that the
pathogens among missed deaths were distributed
equivalently to those among deaths with laboratory
results in the most extreme scenario (100% of deaths
fulfilling the pSBI definition). The overall pathogen
prevalence distribution in ANISA did not change
markedly, with the pathogen proportion attributed to
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Mean (95% CrI)
among babies
who survived

Survived
Died

Mean (95% CrI)
among babies
who died
1·31 (0·19–4·05)

Bordetella spp

0·82 (0·39–1·63)

Chlamydia pneumoniae

0·11 (0·05–0·22)

Chlamydia trachomatis

0·31 (0·17–0·59)

Escherichia coli

1·06 (0·56–1·77)

Group A streptococcus

0·32 (0·29–0·37)

Group B streptococcus

0·77 (0·41–1·21)

2·89 (1·23–5·14)

Klebsiella pneumoniae

1·44 (0·90–2·11)

5·21 (3·09–7·97)

Mycoplasma pneumoniae

*

Neisseria meningitidis

8·70 (5·23–13·36)

0·22 (0·15–0·38)

pan-Haemophilus influenzae

0·54 (0·30–1·13)

Pseudomonas aeruginosa

0·08 (0·03–0·27)

Salmonella spp

1·48 (0·60–2·85)

1·11 (0·52–3·18)

Staphyloccocus aureus

0·84 (0·49–1·36)

Streptococcus pneumoniae

1·08 (0·61–1·93)

Ureaplasma spp

2·71 (1·78–3·72)

8·26 (4·10–12·27)

Other blood culture

2·12 (1·65–2·67)

10·76 (7·88–14·06)

Adenovirus

0·61 (0·32–1·11)

Cytomegalovirus

0·68 (0·17–1·50)

Enterovirus or rhinovirus

1·40 (0·82–2·51)

Human metapneumovirus

0·43 (0·27–0·75)

Human parechovirus

0·21 (0·11–0·40)

Influenza A

0·62 (0·29–1·14)

Influenza B

0·64 (0·46–1·11)

Parainfluenza virus type 1

0·60 (0·38–1·05)

Parainfluenza virus type 2

0·08 (0·04–0·19)

Parainfluenza virus type 3

0·79 (0·51–1·37)

Respiratory syncytial virus

6·66 (5·91–7·82)

Rubella

0·17 (0·10–0·32)
0

2

4

6
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20

3·73 (2·01–6·83)

1·68 (1·00–2·92)

2·14 (1·26–3·20)
22

Proportion of pSBI episodes (%)

Figure 3: Attributed proportions of causal pathogens tested during possible serious bacterial infection
episodes among babies who died and survived, estimated in a partially latent class model
CrI=credible interval. *None detected.

Ureaplasma spp, E coli, and K pneumoniae being
increased to about 3·0–4·0%, and those attributed to
respiratory syncytial virus decreased from 6·5% to
5·3% (appendix).

Discussion
With neonatal deaths fast becoming predominant
among deaths in children younger than 5 years, we
aimed with the ANISA study to use state-of-the-art
microbiology techniques and computational modelling
in one of the largest community-based studies of its kind
to bridge major knowledge gaps and improve estimates
of incidence of neonatal infections and their causes in
south Asia, where 36% of all neonatal deaths occur.
Although causal attribution among babies with pSBI in
our cohort of over 63 000 livebirths was low (28%)
because of the highly sensitive clinical algorithm we
used, we found that bacterial causes predominated over
viral causes. Even more importantly, ANISA captured
data on pathogens associated with pSBI deaths,
indicating that a cause could be attributed in 46% of
deaths, among which most (92%) were bacterial.
156

The incidence of culture-confirmed bacterial pSBI
episodes was 1·6 per 1000 livebirths, which was lower
than previously reported incidence in south Asia (3·0 per
1000 livebirths in Mirzapur, Bangladesh,12 and 6·7 per
1000 livebirths in Odisha, India13). A study in Africa
reported incidence of 5·5 per 1000 livebirths for bacterial
infections among neonates.23 The low frequency of
culture-confirmed pSBI episodes in ANISA might have
stemmed partly from efforts to minimise inclusion of
isolates that were not clinically relevant, strategies to
minimise contamination of samples, and expert review
of positive cultures. Use of the molecular assays and
modelling to attribute causes, however, indicated a
higher proportion of bacterial causes than reported in
previous studies.
Among bacterial causes, Ureaplasma spp predominated,
particularly during the first 3 days of life and among
babies with pSBI who died. The role of this atypical
bacterium as a cause of neonatal morbidity and mortality
is not well understood because it does not grow under
conventional culture methods. Previous associations of
Ureaplasma spp with adverse outcomes in mothers
(chorioamnionitis and extreme preterm delivery) and
neonates (prematurity, sepsis or meningitis, and
pulmonary and cerebral morbidity) have been
documented, as have pSBI episodes in neonates due to
U parvum and U urealyticum.6,24 Common empirical
treatment with β-lactams or cephalosporins is not
effective against Ureaplasma spp due to the lack of a cell
wall.25 Future studies using various methods are needed
to characterise the pathogenic role of Ureaplasma spp in
babies and guide treatment policies.
Over half of bacteria identified as causing pSBI were
Gram negative, particularly Klebsiella spp and E coli.
These bacteria ranked among the top pathogens resulting
in death among babies with pSBI episodes and were
present in all study sites. Blood culture analysis revealed
higher incidence of Gram-negative organisms among
hospital-born babies than among community-born
babies. These findings are consistent with those in
previous studies from south Asia.8,13 The prevalence of
Gram-negative organisms in the environment and on the
body surface of neonates in south Asia might be the
source of these infections.26,27
In concordance with previous data from south Asia,
the incidence of pSBI episodes caused by group B
streptococcus was lower than that reported in Africa.28,29
Attribution was, however, more than 3·7 times more
likely among babies with pSBI who died than among
survivors, and 1·8 times more likely among babies with
early-onset illness than among those with late-onset
illness. These findings suggest that the burden of
group B streptococcus might be underestimated because
of the challenges in capturing samples after early death.
A study done in Bangladesh at the same site as ANISA
showed that mortality was increased by 6·6 times among
neonates with group B streptococcus colonisation of the
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umbilical cord stump.30 Further investigations of early
deaths and a maternal vaccine probe study will be crucial
to understanding the true burden of group B
streptococcus among babies in south Asia.
We collected 349 samples from babies who died, which
exceeds the number of samples obtained from babies
after pSBI-associated deaths in previous studies, yet still
represents only a small proportion of all deaths in the
ANISA catchment areas, despite intensive efforts. This
notable limitation stemmed from the high frequency of
early deaths. 68% of deaths among non-registered babies
occurred within 24 h of birth (median age 6·1 h), among
whom over a quarter died in the first hour of life
(appendix). The challenge of reaching babies before
death also translates into challenges for the treatment
and prevention of illnesses in at-risk babies. Among
those who had pSBI episodes and died, the causative
bacteria were diverse (>25 species within 19 genera),
complicating development of empirical treatment and
prevention strategies. Furthermore, antibiotic therapy
might be given too late to be effective, particularly for
births outside health facilities. Maternal immunisation
has the potential to protect fetuses and neonates from
infection, but maternal vaccines are not available for any
of the leading organisms associated with pSBI deaths.
Interventions such as use of a clean delivery kit at birth
might prevent some early deaths due to infection.
The predominant role of respiratory syncytial virus
(5·4 per 1000 livebirths) among viral causes of pSBI in
the first 2 months of life is consistent with previous
studies in neonates in Bangladesh and Nepal.14,31 Among
babies who had pSBI and died in this study, respiratory
syncytial virus ranked sixth. Respiratory syncytial virus
further stresses under-resourced health systems where
the numbers of hospital beds are small and patients need
continuous care for common sequelae, such as recurrent
wheeze and asthma. The contribution in this study of
respiratory syncytial virus to pSBI, even in the first days
of life, suggests a specific opportunity to intervene and
prevent deaths and morbidity through maternal
immunisation, administration of monoclonal antibodies
to neonates, or both, which are looking likely to become
available options.32,33
Our findings should be considered within the context of
some limitations. First, despite using highly sensitive
diagnostic methods, we could not identify causes in most
(72%) pSBI episodes, and more than half (54%) of fatal
pSBI episodes. The reasons for these outcomes are multi
factorial. First, a subset of episodes could have had
causative agents beyond the 28 prioritised by the expert
panel. The unexpected finding of Ureaplasma spp as
leading causes indicates that organisms that are not
generally judged to be the most common might have
important roles. Genomic analyses have shown that many
bacterial species can only be detected by culture-indepen
dent approaches.34,35 With advances in metagenomics, the
biobank of the ANISA study will provide an opportunity to

probe for additional organisms. Second, ANISA only
captured blood and respiratory samples. Although
cerebrospinal fluid collection was attempted, very few
samples were obtained. We did not try to collect samples
from other sterile sites, such as lung aspirates or urine, or
peripheral sites other than the nasopharynx and
oropharynx. Third, collection of blood and respiratory
samples from healthy babies in the first days of life was
challenging due to difficulties in early birth capture and
community acceptability. Thus, samples from healthy
babies were skewed towards older babies who might have
had more time to acquire organisms from the
environment. Overestimation of background presence of
potential pSBI organisms would, therefore, have
underestimated causal attribution. Fourth, we used
WHO’s Integrated Management of Childhood Illness
algorithm to define pSBI, but this approach emphasises
sensitivity at the cost of specificity.36,37 The standard clinical
signs of pSBI also overlap with those of intrapartumrelated events and other non-infectious causes of neonatal
mortality, making it unlikely that all pSBI episodes are of
infectious origin. Our findings lend support to the
prediction of Mulholland and colleagues38 that only a
limited proportion of babies with pSBI actually have
illnesses of bacterial origin. Moreover, poor specificity
could explain the results of other studies in which
standard and simplified antibiotic regimens (ranging
from 14 to two injections and first-line oral antibiotics)
were equally effective.39–41 We found that 83% of the true
bacterial isolates from pSBI were sensitive to first-line
antibiotics, which suggests that widespread antimicrobial
resistance is not yet deeply rooted in the community.
ANISA has opened several avenues for further
exploration that might uncover new strategies for
improving survival among babies and achieving
Sustainable Development Goal 3. These include application
of the latest metagenomic approaches for improved
characterisation of causal organisms in samples; the role of
Ureaplasma spp, for which studies should be designed to
elucidate management policies; assessment of maternal
immunisation against respiratory syncytial virus infection;
identification of ways to differentiate infectious from noninfectious pSBI (eg, with biomarkers or distinct clinical
signs, metagenomics approaches, and minimally invasive
tissue sampling42); and investigation of factors unrelated to
infection that cause pSBI. Low antibiotic resistance across
south Asian communities provides an incentive to limit
unnecessary antibiotic use to prevent emergence of
antimicrobial resistance.
Contributors
SKS conceived the project and gained funding. SKS, SJS, SEA, AKMZ,
SAQ, ZAB, and AHB designed the study protocol. AKMZ, ZAB, AB, PP,
and AHB supervised the study at their respective sites. JMW, MHD, JLW,
MBH, and LM, did the laboratory and SAQ did the clinical quality and
assurance and quality control. MSI and NEC coordinated the study.
SBS, DKM, RI, YS, SAh, RS, PN, AM, and VRM coordinated collection of
clinical data at field sites. MI, VB, and KP coordinated site-specific
laboratory activities. FK, AH, MH, IR, and JH did the laboratory assays.

www.thelancet.com Vol 392 July 14, 2018
Downloaded for Anonymous User (n/a) at Aga Khan University Hospital from ClinicalKey.com by Elsevier on January 28, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.

157

Articles

MWW, DHH, and PLH led the review process of blood culture isolates.
SEA, LCM, QSu-R, and TH participated in data management.
SJS, LCM, NS, MLA, and AL had full access to all the data in the study
and facilitated data analysis. SKS and SJS wrote the paper with input from
all authors. All authors reviewed and approved the final draft. SKS had the
final responsibility for the decision to submit for publication.
ANISA technical advisory group members
Mathuram Santosham (Chair), Cynthia G Whitney, Derrick W Crook,
Larry J Anderson, Patricia L Hibberd, Stephen P Luby, Shamim A Qazi,
Shams El Arifeen, Abdullah H Baqui, Anita K M Zaidi,
Zulfiqar A Bhutta, Pinaki Panigrahi, Anuradha Bose, and Samir K Saha.
ANISA investigators
Samir K Saha (principal investigator), Dhaka, Bangladesh;
Abdullah H Baqui, Sylhet, Bangladesh; Anita K M Zaidi, Karachi,
Pakistan; Zulfiqar A Bhutta, Matiari, Pakistan; Pinaki Panigrahi, Odisha,
India; and Anuradha Bose, Vellore, India.
Blood culture review committee members
Patricia L Hibberd, Davidson H Hamer, and Martin W Weber.

10
11
12

13

14

15

Declaration of interests
We declare no competing interests.
Acknowledgments
This work was supported by a grant (OPPGH5307) from the
Bill & Melinda Gates Foundation to the Child Health Research
Foundation, Dhaka, Bangladesh. We thank the technical advisory group
members of the ANISA project, the site principal investigators, the
blood culture review committee members, and the independent
experts, Daniel E Roth, Sickkids Hospital and Steve Oberste,
Ann Whitney, and Sanjyot Shinde, Centers for Disease Control and
Prevention, were independent experts, who played active roles in the
study design and implementation process and data analysis. We are
indebted to the study participants and their caregivers, and the study
team members for their contributions. We also thank Senjuti Saha for
editing the manuscript, Mahmudur Rahman for helping with data
management, Mahfuza Marzan for helping with project coordination,
and Saiful Islam for helping to prepare the graphs. The findings and
conclusions in this report are those of the authors and do not
necessarily represent the official position of the US Centers for Disease
Control and Prevention or WHO.
References
United Nations. The Millennium Development Goals Report 2015.
1
2015. http://www.un.org/millenniumgoals/2015_MDG_Report/pdf/
MDG%202015%20rev%20(July%201).pdf (accessed June 4, 2018).
2
Liu L, Oza S, Hogan D, et al. Global, regional, and national causes
of child mortality in 2000–13, with projections to inform post-2015
priorities: an updated systematic analysis. Lancet 2015; 385: 430–40.
3
UNICEF, WHO, World Bank, UN-DESA Population Division.
Levels & trends in child mortality 2014. 2014. http://www.who.int/
maternal_child_adolescent/documents/levels_trends_child_
mortality_2014/en/ (accessed June 4, 2018).
Seale AC, Blencowe H, Zaidi A, et al. Neonatal severe bacterial
4
infection impairment estimates in South Asia, sub-Saharan Africa,
and Latin America for 2010. Pediatr Res 2013; 74 (suppl 1): 73–85.
5
Leung TF, Lam DS, Miu TY, et al. Epidemiology and risk factors for
severe respiratory syncytial virus infections requiring pediatric
intensive care admission in Hong Kong children. Infection 2014;
42: 343–50.
6
Yoon BH, Romero R, Lim JH, et al. The clinical significance of
detecting Ureaplasma urealyticum by the polymerase chain reaction
in the amniotic fluid of patients with preterm labor.
Am J Obstet Gynecol 2003; 189: 919–24.
7
Newton O, English M. Young infant sepsis: aetiology, antibiotic
susceptibility and clinical signs. Trans R Soc Trop Med Hyg 2007;
101: 959–66.
Zaidi AK, Thaver D, Ali SA, Khan TA. Pathogens associated with
8
sepsis in newborns and young infants in developing countries.
Pediatr Infect Dis J 2009; 28 (suppl 1): S10–18.
Seale AC, Blencowe H, Manu AA, et al. Estimates of possible severe
9
bacterial infection in neonates in sub-Saharan Africa, south Asia,
and Latin America for 2012: a systematic review and meta-analysis.
Lancet Infect Dis 2014; 14: 731–41.

158

16

17

18
19

20
21
22
23
24
25

26

27

28

29

Etiology and clinical signs of serious infections in young infants in
developing countries: a WHO collaborative study.
Pediatr Infect Dis J 1999; 18 (suppl 10): S1–69.
Hamer DH, Darmstadt GL, Carlin JB, et al. Etiology of bacteremia
in young infants in six countries. Pediatr Infect Dis J 2015;
34: e1–8.
Darmstadt GL, Saha SK, Choi Y, et al. Population-based incidence
and etiology of community-acquired neonatal bacteremia in
Mirzapur, Bangladesh: an observational study. J Infect Dis 2009;
200: 906–15.
Panigrahi P, Chandel DS, Hansen NI, et al. Neonatal sepsis in
rural India: timing, microbiology and antibiotic resistance in a
population-based prospective study in the community setting.
J Perinatol 2017; 37: 911–21.
Farzin A, Saha SK, Baqui AH, et al. Population-based incidence
and etiology of community-acquired neonatal viral infections in
Bangladesh: a community-based and hospital-based surveillance
study. Pediatr Infect Dis J 2015; 34: 706–11.
Islam MS, Baqui AH, Zaidi AK, et al. Infection surveillance
protocol for a multicountry population-based study in south Asia to
determine the incidence, etiology and risk factors for infections
among young infants of 0 to 59 days old. Pediatr Infect Dis J 2016;
35 (5 suppl 1): S9–15.
Saha SK, Islam MS, Qureshi SM, et al. Laboratory methods for
determining etiology of neonatal infection at population-based sites
in south Asia: the ANISA study. Pediatr Infect Dis J 2016;
35 (5 suppl 1): S16–22.
Diaz MH, Waller JL, Napoliello RA, et al. Optimization of multiple
pathogen detection using the TaqMan Array Card: application for a
population-based study of neonatal infection. PLoS One 2013;
8: e66183.
Lay JO Jr. MALDI-TOF mass spectrometry of bacteria.
Mass Spectrom Rev 2001; 20: 172–94.
Hossain B, Weber MW, Hamer DH, et al. Classification of blood
culture isolates into contaminants and pathogens on the basis of
clinical and laboratory data. Pediatr Infect Dis J 2016;
35 (5 suppl 1): S52–54.
Jehan F, Qazi S. Treating sick young infants with only fast
breathing with oral amoxicillin in resource-limited settings: taking
the high road? Clin Infect Dis 2017; 64: 190–91.
Islam MS, Rahman QS, Hossain T, et al. Using text messages for
critical real-time data capture in the ANISA study.
Pediatr Infect Dis J 2016; 35 (5 suppl 1): S35–38.
Wu Z, Deloria-Knoll M, Hammitt LL, Zeger SL. Partially latent
class models for case-control studies for childhood pneumonia
aetiology. J R Stat Soc 2016; 65: 97–114.
Berkley JA, Lowe BS, Mwangi I, et al. Bacteremia among children
admitted to a rural hospital in Kenya. N Engl J Med 2005;
352: 39–47.
Waites KB, Crouse DT, Cassell GH. Systemic neonatal infection
due to Ureaplasma urealyticum. Clin Infect Dis 1993;
17 (suppl 1): S131–35.
Beeton ML, Chalker VJ, Jones LC, Maxwell NC, Spiller OB.
Antibiotic resistance among clinical ureaplasma isolates recovered
from neonates in England and Wales between 2007 and 2013.
Antimicrob Agents Chemother 2015; 60: 52–56.
Mullany LC, Saha SK, Shah R, et al. Impact of 4.0% chlorhexidine
cord cleansing on the bacteriologic profile of the newborn
umbilical stump in rural Sylhet District, Bangladesh:
a community-based, cluster-randomized trial.
Pediatr Infect Dis J 2012; 31: 444–50.
Ercumen A, Pickering AJ, Kwong LH, et al. Animal feces
contribute to domestic fecal contamination: evidence from E coli
measured in water, hands, food, flies, and soil in Bangladesh.
Environ Sci Technol 2017; 51: 8725–34.
Cutland CL, Schrag SJ, Thigpen MC, et al. Increased risk for
group B streptococcus sepsis in young infants exposed to HIV,
Soweto, South Africa, 2004–2008(1). Emerg Infect Dis 2015;
21: 638–45.
Sinha A, Russell LB, Tomczyk S, et al. Disease burden of group B
streptococcus among infants in sub-Saharan Africa: a systematic
literature review and meta-analysis. Pediatr Infect Dis J 2016;
35: 933–42.

www.thelancet.com Vol 392 July 14, 2018
Downloaded for Anonymous User (n/a) at Aga Khan University Hospital from ClinicalKey.com by Elsevier on January 28, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.

Articles

30

31
32

33

34
35

36

Islam MS, Saha SK, Islam M, et al. Prevalence, serotype
distribution and mortality risk associated with group B
streptococcus colonization of newborns in rural Bangladesh.
Pediatr Infect Dis J 2016; 35: 1309–12.
Chu HY, Katz J, Tielsch J, et al. Respiratory syncytial virus infection
in infants in rural Nepal. J Infect 2016; 73: 145–54.
Novavax. Novavax continues phase 3 trial of the RSV F vaccine for
infants via maternal immunization and provides update on
phase 1/2 trial of the NanoFlu™ vaccine. Dec 18, 2017.
http://ir.novavax.com/news-releases/news-release-details/novavaxcontinues-phase-3-trial-rsv-f-vaccine-infants-maternal
(accessed March 3, 2018).
American Academy of Pediatrics Committee on Infectious
Diseases, American Academy of Pediatrics Bronchiolitis Guidelines
Committee. Updated guidance for palivizumab prophylaxis among
infants and young children at increased risk of hospitalization for
respiratory syncytial virus infection. Pediatrics 2014; 134: 415–20.
Hug LA, Baker BJ, Anantharaman K, et al. A new view of the tree of
life. Nat Microbiol 2016; 1: 16048.
Wilson MR, O’Donovan BD, Gelfand JM, et al. Chronic meningitis
investigated via metagenomic next-generation sequencing.
JAMA Neurol 2018; published online April 16. DOI:10.1001/
jamaneurol.2018.0463..
Young Infants Clinical Signs Study Group. Clinical signs that
predict severe illness in children under age 2 months: a multicentre
study. Lancet 2008; 371: 135–42.

37
38
39

40

41

42

Weber MW, Carlin JB, Gatchalian S, et al. Predictors of neonatal
sepsis in developing countries. Pediatr Infect Dis J 2003; 22: 711–17.
Mulholland K, Carlin JB, Duke T, Weber M. The challenges of trials
of antibiotics for pneumonia in low-income countries.
Lancet Respir Med 2014; 2: 952–54.
Mir F, Nisar I, Tikmani SS, et al. Simplified antibiotic regimens for
treatment of clinical severe infection in the outpatient setting when
referral is not possible for young infants in Pakistan (Simplified
Antibiotic Therapy Trial [SATT]): a randomised, open-label,
equivalence trial. Lancet Glob Health 2017; 5: e177–85.
African Neonatal Sepsis Trial (AFRINEST) Group, Tshefu A,
Lokangaka A, et al. Simplified antibiotic regimens compared with
injectable procaine benzylpenicillin plus gentamicin for treatment
of neonates and young infants with clinical signs of possible serious
bacterial infection when referral is not possible: a randomised,
open-label, equivalence trial. Lancet 2015; 385: 1767–76.
Baqui AH, Saha SK, Ahmed AS, et al. Safety and efficacy of
alternative antibiotic regimens compared with 7 day injectable
procaine benzylpenicillin and gentamicin for outpatient treatment
of neonates and young infants with clinical signs of severe infection
when referral is not possible: a randomised, open-label, equivalence
trial. Lancet Glob Health 2015; 3: e279–87.
Byass P. Minimally invasive autopsy: a new paradigm for
understanding global health? PLoS Med 2016; 13: e1002173.

www.thelancet.com Vol 392 July 14, 2018
Downloaded for Anonymous User (n/a) at Aga Khan University Hospital from ClinicalKey.com by Elsevier on January 28, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.

159

